After Hours
$
267.46
Change
-0.24 -0.09%
Volume
Volume 199,353
Sep 22, 2023, 7:50 p.m.
Quotes are delayed by 20 min
Previous close
$ 269.41
$ 267.70
Change
-1.71 -0.63%
Day low
Day high
$266.52
$269.50

52 week low
52 week high
$211.71
$296.67

Market cap
$143.19B
Average volume
2.54M
P/E ratio
18.05
Rev. per Employee
$1.05M
EPS
14.83
Dividend
2.13
Div yield
3.18%
Ex dividend date
8/17/23
MarketWatch News on AMGN
-
Dow's nearly 100-point rally led by gains for shares of Amgen, IBM
- MarketWatch Automation
-
IBM, Amgen share gains contribute to Dow's nearly 200-point jump
- MarketWatch Automation
-
Dow's 320-point rally led by gains in shares of JPMorgan Chase, Amgen
- MarketWatch Automation
-
Dow's nearly 100-point drop led by losses for shares of Amgen, Procter & Gamble
- MarketWatch Automation
-
These four Dow stocks take top prizes for dividend growth
- Philip van Doorn
-
Amgen, FTC Settle Over $27.8 Billion Horizon Deal
- Karishma Vanjani
-
These Stocks Led the Market in August. It's Still Tech's Year.
- Angela Palumbo
-
First 10 Drugs Picked for Medicare Price Negotiations
- Bill Alpert
-
Biden Administration to Reveal 10 Drugs for Which Medicare Will Pay Less
- Josh Nathan-Kazis
- Loading more headlines...
Analyst Ratings
-
Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
- MarketRealist.com
-
Analysts’ Latest Recommendations on Mylan
- MarketRealist.com
-
Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical
- MarketRealist.com
Other News on AMGN
-
A New Way to Protect Against Heart Attacks
- The Wall Street Journal Interactive Edition
-
Big Pharma’s Battle With the Biden Administration Could Have Legs
- The Wall Street Journal Interactive Edition
-
Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
- The Wall Street Journal Interactive Edition
-
Amgen’s Deal for Horizon Therapeutics Clears Key Hurdle
- The Wall Street Journal Interactive Edition
-
Drug Price Controls Mean Slower Cures
- The Wall Street Journal Interactive Edition
-
Expensive Drugs Targeted for First U.S. Price Negotiations
- The Wall Street Journal Interactive Edition
-
FTC Pauses Challenge to Amgen’s $27.8 Billion Deal for Horizon Therapeutics
- The Wall Street Journal Interactive Edition
-
Biotech M&A Rebound Bodes Well for Venture Investors
- The Wall Street Journal Interactive Edition
-
Apple, Amazon, Starbucks to Report in Packed Earnings Week
- The Wall Street Journal Interactive Edition
-
How AbbVie’s Humira Still Reigns, Despite New Competition
- The Wall Street Journal Interactive Edition
-
A Soap Maker Cracks the Code to ‘Made in America’
- The Wall Street Journal Interactive Edition
-
Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
- The Wall Street Journal Interactive Edition
-
Lina Khan Is Taking on the World’s Biggest Tech Companies—and Losing
- The Wall Street Journal Interactive Edition
-
The Drugs That Are Gaining on Ozempic
- The Wall Street Journal Interactive Edition
-
Even Mark Cuban Can’t Fix This Broken Drug System
- The Wall Street Journal Interactive Edition
-
Elizabeth Warren and the FTC Are the Least of Amgen’s Problems
- The Wall Street Journal Interactive Edition
-
Walmart, Tesla, Micron: Stocks That Defined the Week
- The Wall Street Journal Interactive Edition
-
Antitrust Gone Wild Against Amgen
- The Wall Street Journal Interactive Edition
-
Sanofi Wins Supreme Court Patent Dispute With Amgen
- The Wall Street Journal Interactive Edition
-
FTC Moves to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics
- The Wall Street Journal Interactive Edition
- Loading more headlines...
Press Releases on AMGN
-
AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS
- PR Newswire - PRF
-
- Newsfile Corp
-
- Newsfile Corp
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com